Recent data confirm that certain cancers, particularly hematologic, occur more frequently in SLE than in the general population. Numerous pathogenic mechanisms are possible, but hypotheses remain largely speculative. In particular, data are inadequate on how cancer risk in SLE may be related to medication exposures. To evaluate the impact of medication exposures on cancer risk in SLE, cooperative efforts of SLICC and CaNIOS are currently in progress. This should provide much-needed insight into the pathogenesis of the association between cancer and SLE.
ASJC Scopus subject areas